Connecticut wants to throw away “white fence, stone wall” because it promotes the life sciences industry – Hartford Courant

NEW HAVEN – A decade after Connecticut pushed for the development of the life sciences sector, companies, university partners and the state want to develop new ways to market a $ 6 billion industry.

First, the promoters want to change the image of the state as a suburban enclave of the 1950s.

The opposite is true, speakers at the recent Yale Innovation Summit in New Haven said. The Connecticut coastline, meanwhile, is seen as a multiethnic site that offers a rare opportunity for researchers and entrepreneurs to market the region with particular effectiveness in medical and pharmaceutical research and testing.

“I think we still have work to do to change the perception of Connecticut as a white and stone wall,” said Peter Denious, CEO of AdvanceCT, which seeks to hire and maintain businesses in Connecticut. “Boston is incredibly competitive. Our market is almost saturated.

“I think we’re just getting started.”

Prime Minister Ned Lamont said business executives say they want lively city centers to attract “workers over the age of 20”.

“We have a reputation for not being so diverse, and it’s very pretty little houses in the suburbs and you get a little older and have 1.8 kids, then you move to an acre of land from there,” he said. “And that didn’t work anymore today.”

Other benefits are highlighted by the promoters of the Connecticut life sciences industry. Despite complaints about the cost of doing business and living in Connecticut, the state can sell it below the stratospheric costs of urban areas like Boston and San Francisco.

And the development of Tweed New Haven Airport will provide more links for investors, researchers and entrepreneurs.

The diverse population of the region could also play a role in promoting the life sciences industry. David Rosenthal, an assistant professor at Yale School of Medicine and CEO of Tesseract Health Inc., the CEO of Guilford Health Technology, cited New Haven as a rare opportunity to market demographics as demographically representative of the United States.

In terms of age, level of education, and race and ethnicity, the New Haven-Milford region is “the most American” among U.S. cities, Jed Kolko, Secretary of Commerce for Economic Affairs, said in a 2016 Census and other data analysis and published. Five by twenty-eight.

“There are many reasons to be deeply concerned about places that are demographically different from today’s America,” Kolko wrote. “Some of these places may become the protectors of a future America that is older, educated, and racially and ethnically diverse than it is today; and some of these places deserve special public attention and investment because they are in a worse situation than most other places. ”

Rosenthal said the New Haven-to-Milford region’s community of life sciences can market itself as home to a diverse population, and offers a wide range of clinical trial and research opportunities for medical specialists.

“We have a wealth here, unlike in Boston, unlike in New York, unlike in San Francisco,” he told Yale forum attendees.

In an interview, Rosenthal said the state and others involved in the Connecticut life sciences industry have not been made aware of the importance of the diverse population in the region for medical research. For example, he said, some pulse oximeters that measure blood oxygen levels cannot accurately measure low oxygen levels among blacks. One study has shown that this can delay proper treatment.

And hospitals can calculate kidney function differently because the bias of the system was incorporated into an algorithm, Rosenthal said.

“It’s important to have a diverse sample size in research,” he said. “Otherwise, the differences may worsen.”

An AdvanceCT report states that 1,000 life science establishments in Connecticut support 23,600 jobs and generate $ 6 billion in economic output. Funding for pharmaceutical and biotechnology venture capital was $ 700 million in 2021, more than double the 2019 amount.

Paul Pescatello, executive director of the Connecticut Bioscience Growth Council, said the state has done a good job of promoting the growth of the biosciences industry. But he said legislation proposed to limit pharmaceutical prices would undermine those efforts.

The legislation, critics say, would weaken innovation as it prevented drug companies from recovering their investment, which was not advanced in the legislature until the end of May 4th.

“If you’re trying to attract an industry, why push a policy that’s anathema to them?” Pescatello said. “You’re working against me to market the statue.”

State Sen. Christine Cohen, D-Guilford and president of the parliamentary Bioscience Caucus, said pharmaceutical companies had expressed “concern,” but lawmakers also heard about consumers struggling with expensive drugs.

“It’s always a balance,” he said.

Five things you need to know

Five things you need to know

Every day

We are providing the latest coronary heart disease coverage in Connecticut every weekday morning.

Elected officials, activists, and others took the leverage of government, private investment, and health care and research organizations to establish a life sciences industry in Connecticut.

Then-Gob. In 2012, Dannel P. Malloy moved the Maine Research Center, a gene or genetic material in a cell or organ, to the Jackson Laboratory in 2012 to attract high-skilled, well-paid jobs to the state. The General Assembly has set up a $ 200 million Bioscience Innovation Fund to promote innovation in smaller businesses, and tax credits for investors have become law.

In addition, Connecticut Innovations, the state’s venture capital fund, has invested about $ 129 billion in more than 80 companies and projects taking advantage of more than $ 1.7 billion since 2012 in New Haven County health care companies, said Lauren Carmody, vice president of marketing and communications.

And researchers and activists from coastal communities and New Haven have created a number of life sciences businesses at Yale University and work at Yale New Haven Hospital.

The industry’s presence in Connecticut is “relatively new,” but it has grown rapidly, Cohen said, with more than two dozen bioscience companies operating in Branford alone.

“We saw a flooded bubble like Cambridge and people started looking for new places to settle,” he said.

Stephen Singer can be contacted at [email protected]

Leave a Comment